Chart for ongoing monitoring during Amfexa® (dexamfetamine sulfate) treatment

As outlined in the prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored:

Date of initial assessment: ______ Patient name: _____

- Blood pressure and pulse should be recorded at each adjustment of dose and then at least every 6 months
- Height, weight and appetite should be recorded at least 6-monthly with maintenance of a growth chart
- Development of *de novo* or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit

Date of birth: _		 Age: Gender:						
	Baseline	Subsequent appointments						
Date of								
assessment								
Reason for								
assessment								
Blood								
pressure*								
Heart rate*								
Body								
weight								
(kg)**								
Height								
(cm)**								
Appetite								

Date of preparation: March 2022

^{*}Blood pressure and heart rate should be recorded at each adjustment of dose and then at least every 6 months

^{**}Height, weight and appetite should be recorded at least 6-monthly with maintenance of a growth chart

For further information please refer to Amfexa SmPCs:

- Amfexa® 5 mg Tablets SmPC
- Amfexa® 10 mg Tablets SmPC
- Amfexa® 20 mg Tablets SmPC

Local Distributor
EJ Busuttil Ltd
Busuttil Buildings, Triq I-Ghadam, Central Business District Zone 1
Birkirkara
Tel 00356 21447184

rp@ejbusuttil.com

Date of preparation: March 2022